Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merck & Co
(NY:
MRK
)
117.23
-1.41 (-1.19%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
92
93
Next >
Is Summit Therapeutics a Buy Now?
September 10, 2024
The clinical-stage drugmaker's cancer therapy candidate outperformed Keytruda, the world's top-selling cancer drug.
Via
The Motley Fool
Why Summit Therapeutics Rocketed Over 60% Today
September 09, 2024
The company's new lung cancer treatment could unseat Merck's Keytruda in the $50 billion-plus lung cancer treatment market.
Via
The Motley Fool
Methanex, Merck And Other Big Stocks Moving Lower In Monday's Pre-Market Session
September 09, 2024
Via
Benzinga
Biotech Stocks: Lung Cancer Treatment Outflanks Merck's Keytruda
September 09, 2024
Summit shares jumped Monday after positive late-stage indications vs. Merck's Keytruda. The biotech stock rallied 30%.
Via
Investor's Business Daily
Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half
September 09, 2024
Summit Therapeutics shared Phase 3 HARMONi-2 trial data of ivonescimab, showing significant improvement in progression-free survival compared to Merck's Keytruda in non-small cell lung cancer patients,...
Via
Benzinga
What's Wrong With Merck's Stock?
September 05, 2024
Is the healthcare stock an underrated buy right now?
Via
The Motley Fool
(MRK) - Analyzing Merck & Co's Short Interest
September 03, 2024
Via
Benzinga
Behind the Scenes of Merck & Co's Latest Options Trends
August 30, 2024
Via
Benzinga
Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
September 09, 2024
Via
Benzinga
3 No-Brainer Dividend Stocks to Buy in September
September 08, 2024
These stocks pay great dividends and could be long-term winners.
Via
The Motley Fool
Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
September 07, 2024
From
Daiichi Sankyo
Via
Business Wire
Uncovering Dividend Opportunities with NYSE:MRK.
August 30, 2024
Why MERCK & CO. INC. (NYSE:MRK) qualifies as a good dividend investing stock.
Via
Chartmill
Is Merck Stock Undervalued After Its Colossal Earnings Growth?
September 07, 2024
Merck has seen its earnings invert over the past 12 months, driving earnings grow in its sector. What's going on with this pharma giant?
Via
MarketBeat
Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock
September 06, 2024
Wall Street analysts see big potential upside for small-cap biopharma firm Trevi Therapeutics. So, what does the firm do and how does it stand out?
Via
MarketBeat
Exposures
Product Safety
What's Going On With Merck Shares Thursday?
September 05, 2024
Merck stock is trading higher on Thursday after the company announced it completed negotiations with the pan-Canadian Pharmaceutical Alliance.
Via
Benzinga
Down a Monstrous 90% This Year, Is There Any Hope Left for Ginkgo Bioworks Investors?
September 05, 2024
Could this beaten-down stock turn things around in the near future?
Via
The Motley Fool
The Smartest Dividend Stocks to Buy With $5,000 Right Now
September 05, 2024
These stocks have a long history of increasing dividends.
Via
The Motley Fool
Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024
September 04, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™ for the Treatment of Diabetic Macular Edema
September 04, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street
September 03, 2024
Merck flirts with bearish trends; Gilead is on a golden streak. Who wins? Investors should keep an eye on these diverging technical signals.
Via
Benzinga
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
September 03, 2024
Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
10 Health Care Stocks With Whale Alerts In Today's Session
September 03, 2024
Via
Benzinga
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults
September 03, 2024
From
Merck & Co., Inc.
Via
Business Wire
2 Dividend Stocks You Can Safely Hold Through a Recession
September 02, 2024
These stocks can help you sleep peacefully at night, even in bad times.
Via
The Motley Fool
Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales
August 29, 2024
BioNTech and Moderna are advancing personalized cancer vaccines using mRNA technology. Despite promising early results, these innovative treatments face challenges in cost, scalability, and...
Via
Benzinga
Exposures
COVID-19
Merck Pulls Plug On Two Keytruda Late-Stage Studies On Underwhelming Data
August 29, 2024
Merck discontinues two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630, for Keytruda in lung cancer and cutaneous squamous cell carcinoma. Independent committees found no survival benefit and higher...
Via
Benzinga
Merck to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 29, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials
August 29, 2024
From
Merck & Co., Inc.
Via
Business Wire
Dow Jones Industrial Average Pares Recent Gains As Investors Take A Pause
August 28, 2024
The Dow Jones Industrial Average (DJIA) trimmed near-term gains on Wednesday, backsliding 150 points in the midweek market session.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
12 Dividend Stocks to Earn Income Every Month
August 28, 2024
Get paid a dividend on a monthly basis.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
92
93
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.